Baxter has announced the appointment of a new head of medical products as part of a wider reshuffling of the firm's organisational structure.
Robert Davis has been named as corporate vice-president and president of the newly-formed business unit, which combines the activities of its former renal and medication delivery divisions.
The appointment of former renal business head Mr Davis coincides with the departure of Peter Arduini, Baxter's corporate vice-president and president for medication delivery, who leaves the company to pursue another opportunity.
In addition to these changes, Baxter has also announced Ludwig Hantson as the new head of its bioscience division, replacing Joy Amundson.
Robert Parkinson Jr, chairman and chief executive officer, said: "This new organisation reinforces Baxter's commitment to maintaining a diverse business model while accelerating the company's ongoing efforts to lower cost and drive productivity."
Last month, Baxter published a report on its new Xenium Plus dialyser unit that highlights the environmental and sustainability benefits it offers to users.See all the latest jobs in Medical Devices